Individual tolerance varies based on dose level and individual metabolism
On the other hand, the central narrative survives: that Novo and Lilly aggressively marketed GLP-1 drugs for weight loss while concealing known risks, reaping billions in the process
Despite its widespread use, studies have suggested a possible association between semaglutide and NAION [3,4,5]
After the initial 50% reduction in mealtime insulin dose, individualize insulin dose adjustments based on glycemic control and tolerability (e.g., if nausea occurs it may affect the dose of insulin required)
Many patients taking semaglutide are also advised to make lifestyle changes, like improving their diet and increasing their water intake, to help manage their diabetes or weight